deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05105412

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

A Single Arm，Phase Ib/II Study of the Combination of Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas (PTCL)

Sponsor: Chang Gung Memorial Hospital

Conditions Peripheral T-cell Lymphomas (PTCL)
Interventions Lenalidomide and Gemcitabine (Dose level 11) Lenalidomide and Gemcitabine (Dose level 21) Lenalidomide and Gemcitabine (Dose level 31) Lenalidomide and Gemcitabine (Dose level 41)
Updated 6 times since 2021 Last updated: Jul 3, 2024 Started: Jun 15, 2022 Primary completion: Mar 30, 2024 Completion: Mar 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The resolution of DSMB

Other terminated trials from Chang Gung Memorial Hospital

See all terminations from Chang Gung Memorial Hospital

This PHASE1/PHASE2 trial investigates Peripheral T-cell Lymphomas (PTCL) and is currently terminated or withdrawn. Chang Gung Memorial Hospital leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotNot Yet Recruiting~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshotNot Yet Recruiting~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshotTerminated~Dec 2025 – present · 7 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Status: Not Yet Recruiting → Terminated

  5. Jul 2024 — Aug 2024 [monthly]

    Not Yet Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 1 earlier version

  1. Dec 2021 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chang Gung Memorial Hospital
  • China Medical University Hospital
  • National Cheng-Kung University Hospital
  • National Health Research Institutes, Taiwan
  • National Taiwan University Hospital
Data source: National Health Research Institutes, Taiwan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations